Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 4,180.6 million in 2020 and is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The global urinary incontinence treatment drugs market growth is driven by high incidence and increasing prevalence of urinary incontinence across the globe and increasing product approvals by regulatory authorities.

According to Integrated Care for Older People (ICOPE) guidelines by World Health Organization (WHO), a population based study was carried out in 2017, an ‘Evidence profile: urinary incontinence’, in the U.S. and Nordic countries (Denmark, Norway, Sweden). It reported that the prevalence of urinary incontinence was ranging from 9.9% to 36.1% and was high in older women than the older men.

For instance, in March 2020, Urovant Sciences, Inc announced that it received the U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Vibegron for the Treatment of patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Urinary Incontinence Treatment Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

The rapid spread of COVID-19 is challenging for healthcare systems worldwide. In many countries, hospitals and ICU departments are overloaded or fearing potential collapse of healthcare resources that are required for treatments in ICU.

Since December 2019, a novel coronavirus spread throughout China and across the world, causing a continuous increase in confirmed cases within a short period of time. The disease has spread to more than 200 countries across the globe with the World Health Organization declaring it a public health emergency.

According to the World Health Organization Coronavirus Disease (COVID-19) Dashboard (WHO) report, the manifestation of the coronavirus disease (COVID-19) has resulted in more than 64.9 million infected individuals worldwide as of December 5, 2020.

Browse 35 Market Data Tables and 36 Figures spread through 180 Pages and in-depth TOC on Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027"

To know the latest trends and insights related to urinary incontinence treatment drugs market, click the link below:

https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400

Key Takeaways of the Urinary Incontinence Treatment Drugs Market:

  • The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to increasing prevalence of urinary incontinence across the globe and increasing product approvals by regulatory authorities
  • Among drug class, the anticholinergic agent segment is expected to hold a major revenue share in 2027. The anticholinergic agents, oxybutynin (Ditropan; Oxytrol) and tolterodine (Detrol), are used widely to treat urge incontinence.
  • Major players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.